Symbiotec Pharmalab Limited

Symbiotec Pharmalab Limited is a research and development-driven, science-based pharmaceutical and biotechnology company. The company’s core value proposition lies in its specialized capabilities across three key technological platforms: organic chemistry, biotechnology, and complex injectables. Operating on a vertically integrated, asset-light, and cost-efficient business model, Symbiotec functions as a cohesive "farm-to-pharmacy" and "microbe-to-pharmacy" platform. By converting commodity, plant-based derivative inputs into high-value steroid and hormonal pre-cursors, the company has successfully integrated backward to achieve self-sufficiency, enabling strategic, cost-effective "make versus buy" decisions for key starting materials (KSMs) representing over 80% of its product portfolio by revenue.

The company serves a highly diversified B2B customer base comprising over 200 distinct customers across more than 40 countries, including leading generic and specialty pharmaceutical innovators and formulations manufacturers in the United States, Europe, and Asia. Its target demographics comprise cost-conscious yet clinically stringent pharmaceutical formulations companies that require consistent, high-purity API supplies. Geographically, Symbiotec’s sales and operating footprint are heavily globalized, with revenue from external customers outside India representing 67.04% (Rs 582.64 Cr) of total revenue from operations in Fiscal 2026, compared to 55.19% (Rs 414.78 Cr) in Fiscal 2025 and 59.97% (Rs 429.52 Cr) in Fiscal 2024. The company exhibits strong customer stickiness, maintaining relationship tenures exceeding ten years with its top five and top ten customers.

The company's core physical and manufacturing infrastructure is located in Madhya Pradesh, India, and is divided into four industrial-scale facilities. The Rau Facility (22,970 sq. meters, owned) specializes in sterile and non-sterile corticosteroid APIs, carrying a maximum chemical synthesis capacity of 92.00 MT with a Fiscal 2026 capacity utilization of 63.49%. The Pithampur Facility (53,864 sq. meters, owned) houses dedicated steroidal-hormone blocks, carrying a maximum chemical synthesis capacity of 492.67 MT (utilized at 83.47% in FY26) and a fermentation capacity of 300.00 KL (utilized at 72.91% in FY26). In addition, the company has recently commissioned the Ujjain Facility, an industrial biomanufacturing plant equipped with a fermentation capacity of 400.00 KL (housing four high-volume fermenters of 100 KL each), and the Mhow Facility, a specialized complex injectables plant capable of producing up to 20 million double chamber vials (DCVs) per annum.

A primary competitive moat for the company is its extensive in-house research and development framework, which comprises three dedicated R&D centers in Indore, Madhya Pradesh, focusing on organic chemistry, biotechnology, and complex injectables. As of March 31, 2026, the company’s R&D team consisted of 156 scientists and engineers, including 117 master’s degrees and 10 PhDs, who drive continuous process improvement, strain development, and lifecycle management. Symbiotec has made significant, consistent investments in R&D, spending Rs 29.70 Cr (3.42% of revenue) in Fiscal 2026, Rs 31.14 Cr (4.14% of revenue) in Fiscal 2025, and Rs 20.51 Cr (2.86% of revenue) in Fiscal 2024. This R&D-led capability is demonstrated by its robust regulatory credentials, which include 43 active US Drug Master Files (DMFs) registered with the US FDA and 23 valid Certificates of Suitability (CEPs) from the EDQM.

As per financial performance, Symbiotec Pharmalab Limited has posted total income / net profits of Rs 723.33 Cr / Rs 100.06 Cr (FY24), Rs 755.98 Cr / Rs 96.79 Cr (FY25) and Rs 872.26 Cr / Rs 109.90 Cr (FY26). So as per previous financials data, the company has shown steady, consistent top-line expansion, with revenue from operations compound-growing at a CAGR of 10.16% over the last two fiscals, while its total borrowings rose to Rs 540.92 Cr in FY25 before successfully reducing to Rs 387.91 Cr in FY26 due to disciplined debt management and strategic prepayments on its long-term borrowings. Company has an average EPS of Rs 18.29 (diluted weighted average, or Rs 18.35 basic weighted average) and average RoNW of 10.99% for the last three fiscals. Based on the pre-issue book value, the issue is priced at a Pre-Issue P/BV of 5.35 as per NAV of Rs 184.69 as on 31.03.26. Factoring in the fresh issue proceeds, the Post-Issue P/BV stands at 4.85 (calculated on the post-issue expanded NAV of Rs 203.67 per share). If we attribute the latest earnings of FY24, FY25, and FY26 to the expanded equity base post-issue (~6.43 Cr shares), then the asking price is at a Post-Issue P/E of around 63.45, 65.59, and 57.76 respectively based on consolidated net profit (or around 63.37, 65.59, and 57.77 respectively if attributing earnings strictly to the owners of the parent company). As per RHP, a comparison between listed peers shows closest listed competitors Concord Biotech Limited trading at a trailing P/E of 61.07, Divi's Laboratories Limited trading at a trailing P/E of 87.80, and Laurus Labs Limited trading at a trailing P/E of 109.36, placing the industry average P/E at 88.32, which demonstrates that Symbiotec's post-issue trailing FY26 P/E of 57.76 is competitively priced at a steep discount relative to its peer group.

On BRLM's front, JM Financial Limited, Avendus Capital Private Limited, Motilal Oswal Investment Advisors Limited, and Nomura Financial Advisory and Securities (India) Private Limited are associated with this IPO, and lead manager JM Financial Limited has handled 46 IPOs in the last three fiscal years (including the current fiscal till date). (As per RHP)

• 1 Anil Satwani
• 2 Kashish Satwani
• 3 Sushil Satwani
• 4 Satwani Holdings LLP